Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET Imaging

Posted by Andrew W. Hahn, MD | Aug 2024

Andrew W. Hahn, MD, presented “Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET Imaging” during the 34th International Prostate Cancer Update on February 13, 2024, in Vail, Colorado.

This content is available free to the GRU Community. Login or create an account to view it.

Create an Account

How to cite: Hahn, Andrew W. “Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET Imaging.” February 2024. Accessed Aug 2024. https://grandroundsinurology.com/treatment-of-oligometastatic-prostate-cancer-in-the-era-of-psma-pet-imaging/

Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET Imaging – Summary

Andrew W. Hahn, MD, explores the treatment of oligometastatic prostate cancer in the context of advancements in PSMA PET imaging. Dr. Hahn examines the integration of systemic therapies with local treatments, discussing the benefits and challenges of combining androgen deprivation therapy (ADT) with newer agents like androgen receptor inhibitors and chemotherapy. The presentation also delves into the evolving role of PSMA-targeted radioligand therapy, outlining promising results from early-phase studies and ongoing research on this treatment modality.

A significant portion of the presentation is dedicated to the practical considerations and challenges associated with implementing PSMA PET imaging and MDT in clinical practice. Dr. Hahn addresses issues related to accessibility, cost, and the need for multidisciplinary collaboration to ensure the best patient outcomes.

About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.

About The Author

Andrew W. Hahn, MD

Dr. Andrew Hahn is an Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center. Andrew earned a Bachelor of Arts in Synthetic Medicinal Chemistry and his Medical Doctorate at the University of Tennessee. Dr. Hahn completed Internal Medicine residency and a Chief Medicine Resident year at the University of Utah followed by his Medical Oncology fellowship at MD Anderson Cancer Center. His clinical focus is on prostate and kidney cancers. His research focus is to investigate how host factors influence response, resistance, and toxicity to cancer treatments and to design and run clinical trials to improve outcomes for patients with prostate and kidney cancer. Dr. Hahn has published over 40 peer-reviewed original research articles and authored or co-authored 30 other editorials, reviews, and book chapters. His work has been supported by an ASCO Conquer Cancer Foundation Young Investigator Award, Prostate Cancer Foundation Young Investigator Award, and a Department of Defense Early Investigator Research Award.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat